###begin article-title 0
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 232 240 232 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
Common genetic variation in the complement component 1 inhibitor gene () was recently reported to increase the risk of developing age-related macular degeneration (AMD). This study was performed to replicate the association between SERPING1 and AMD.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 490 493 490 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 544 553 544 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 596 601 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB/C2</italic>
###xml 685 687 685 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 114 118 <span type="species:ncbi:162683">Mayo</span>
Seven single nucleotide polymorphisms (SNPs) tagging common haplotypes across SERPING1 were genotyped on 786 (The Mayo Clinic) subjects and the association with AMD studied using single SNP and haplotype association analyses. The SNP in intron 6 () previously reported to increase the risk of AMD was studied in an additional 1,541 subjects from the Age-Related Eye Disease Study (AREDS). Association with specific subtypes of AMD and interaction with four other loci: complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2/LOC387715), High Temperature Requirement Factor A1 (HTRA1), complement factor B/complement component 2 (CFB/C2), and complement component 3 (C3) involved in AMD was explored.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 198 206 198 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 55 59 <span type="species:ncbi:162683">Mayo</span>
###xml 128 132 <span type="species:ncbi:162683">Mayo</span>
The seven tag-SNPs were not associated with AMD in the Mayo subjects (p=0.13-0.70) and  was also not associated with AMD in the Mayo or AREDS subjects (p=0.44-0.45). Evaluation of haplotypes across SERPING1 did not reveal association with AMD (p=0.14-0.97). SNPs were not associated with AMD subtypes (early, geographic atrophy, or exudation). No interaction with other AMD risk variants was observed.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 61 69 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
We were unable to replicate the reported association between SERPING1 and AMD in two independent groups of subjects.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH)</italic>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB)/</italic>
###xml 508 512 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(C2)</italic>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 546 549 546 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3)</italic>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 1019 1021 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1185 1195 1185 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/</italic>
###xml 1235 1240 1235 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 1264 1266 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
Age related macular degeneration (AMD) is a leading cause of irreversible loss of vision in older individuals [1]. Both genetic and cell biologic analyses support a role for dysregulation of innate immunity in the pathogenesis of AMD. Extensive deposition of innate immunity proteins at the level of Bruch's membrane [2,3] in AMD patients has been consistently observed. Genetic variants in complement pathway genes including complement factor H (CFH) [4-6], complement factor B (CFB)/complement component 2 (C2) [7], and complement component 3 (C3) [8-11] are established risks for developing AMD. The association between AMD and genetic variation in these loci has been extensively replicated as recently reviewed [12]. Many other common genetic variants have been proposed for AMD. However, review of a partial list shows that they do not yet have sufficient support due to the absence of replication studies [13-20] or failure to consistently replicate the genetic association in independent groups of subjects [21-29]. Thus, at this time there is strong evidence for the involvement of genetic variation in genes of the alternative pathway of complement and one additional locus (LOC387715/High Temperature Requirement Factor A1 [HTRA1]) on chromosome 10q26 [30,31].
###end p 11
###begin p 12
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
Recently, there has been interest in exploring the genes involved in classical complement activation initiated by antibody-antigen interactions. Evidence for a possible role of the classical complement pathway comes from the observation of anti-retinal antibodies in patients with AMD [32-35], animal models with AMD-like pathology [36], and expression of these proteins in the aging retina and retinal pigment epithelium (RPE) [37].
###end p 12
###begin p 13
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
The complement component 1 (C1) inhibitor is a key regulator of the classical pathway and has been reported to down-regulate the alternative pathway in vitro by binding to C3b and inhibiting binding of complement factor B to C3b [38]. The C1 inhibitor has sequence homology with serine protease inhibitors (SERPIN) and inhibits activation of the classical and lectin compliment pathways by inhibiting the protease activity of complement component 1, r subcomponent (C1r), complement component 1, s subcomponent (C1s), and mannan-binding lectin serine peptidase 2 (MASP-2) [39,40]. The C1 inhibitor also regulates vascular permeability by inhibiting proteases that generate bradykinin [40], as manifested when deficiency of C1 inhibitor results in hereditary angioedema [41-43]. Thus, C1 inhibitor is an excellent candidate gene for involvement in AMD and retinal aging.
###end p 13
###begin p 14
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB/C2</italic>
###xml 231 233 231 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 555 563 555 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 747 755 747 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
Since the discovery of the association between AMD and variants in CFH, the systematic study of other genes regulating or involved in the alternative pathway of complement activation has been productive (e.g., the study of CFB/C2, C3 [7-11]). The systematic study of other genes involved in innate immunity is ongoing in several laboratories. A recent study reported a protective effect on AMD for the minor allele of a SNP () within intron 6 of the  gene encoding the C1 inhibitor [13]. The purpose of this study was to replicate the association between SERPING1 and AMD in two independent groups of subjects. We performed a systematic analysis of all common haplotypes (ancestral segments of DNA inherited as a block in a population) across the SERPING1 locus and identified no evidence for association with AMD.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 802 804 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 1122 1124 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 1574 1576 1572 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 1756 1764 1754 1762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 64 68 <span type="species:ncbi:162683">Mayo</span>
###xml 157 161 <span type="species:ncbi:162683">Mayo</span>
###xml 811 815 <span type="species:ncbi:162683">Mayo</span>
The study was approved by the institutional review board of the Mayo Clinic (Rochester, MN) and written informed consent was obtained from all subjects. The Mayo subjects were composed of 786 Caucasian individuals (476 AMD cases, 310 controls without AMD). Subjects and cases were obtained from the same eye clinics of participating physicians. Diagnosis was determined by review of fundus photographs as described previously [4,44,45]. Briefly, all subjects diagnosed with AMD had large drusen (>/=125 microns) with sufficient drusen area to fill a 700 micron circle or more advanced findings. Controls had 5 or fewer hard drusen (<63 microns) without pigment changes or more advanced findings. Geographic atrophy and exudation were defined using the Wisconsin age-related maculopathy grading system [46]. The Mayo subjects have been graded multiple independent times by Dr. Edwards and were recently re-graded by Dr. Park. Replication studies were performed on 1,541 Caucasian subjects (1,241 with AMD and 300 controls without AMD) from the Age-Related Eye Disease Study (AREDS) that were graded as reported previously [47]. The final AREDS phenotype grade was used. All control grades (controls and control questionable 1-4) were treated as controls. Early AMD consisted of all grades of large drusen (large drusen and large drusen questionable 1-3). Review of genotype frequencies for the control questionable and large drusen questionable AREDS subjects at known AMD risk variants showed that the questionable groups closely matched their assigned group (e.g., for the C3 SNP , genotype frequencies were within 1% when the questionable control or large drusen categories were excluded). Further, the maximal difference in genotype frequencies for the SERPING1 SNP  was 0.03.
###end p 17
###begin p 18
###xml 1200 1207 1200 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 168 172 <span type="species:ncbi:162683">Mayo</span>
###xml 931 935 <span type="species:ncbi:162683">Mayo</span>
###xml 1161 1165 <span type="species:ncbi:162683">Mayo</span>
Advanced AMD AREDS subjects consisted of all advanced AMD grades (questionable advanced, neovascular, geographic atrophy, and both neovascular and geographic atrophy). Mayo or AREDS subjects with both neovascular and geographic atrophy were included in the analysis for each subtype, except when the analytical model required a unique grade. When a unique grade for each subject was required, the subjects graded both were added to the grade with a smaller number of subjects (geographic atrophy) to increase power. Individual SNP analyses were done with and without both, and no differential effect was observed. Eighty-seven subjects with the questionable advanced AMD grade only were used for any AMD versus control analyses. Note that the number of subjects shown in the tables may be less than the total number of subjects available for study, due to failed genotyping. No detectable substructure has been observed within the Mayo subjects that might inflate case-control statistics, and the small amount of sub-structure within the AREDS subjects had no effect on the individual SNP case-control statistics. Demographic and phenotypic information for the Mayo and AREDS subjects is provided in Table 1.
###end p 18
###begin title 19
###xml 43 47 <span type="species:ncbi:162683">Mayo</span>
Demographic and phenotypic features of the Mayo and AREDS subjects
###end title 19
###begin p 20
###xml 183 187 <span type="species:ncbi:162683">Mayo</span>
*Eighty-seven AREDS subjects with the "questionable advanced age-related macular degeneration (AMD)" grade were used as described in Methods, but are not included in this table. **29 Mayo subjects and 85 AREDS subjects who had both geographic atrophy and exudative AMD (category "Both") were included in the geographic atrophy group as described in the Methods. Abbreviations: SD is standard deviation.
###end p 20
###begin title 21
Selection of tag and functional SNPs
###end title 21
###begin p 22
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 845 853 845 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
SNPs genotyped in the international haplotype map () [48] were used to select tag SNPs. SNPs across SERPING1 including 5 kb up and downstream were evaluated for linkage disequilibrium (LD) using ldSelect [49] and a custom algorithm for tag-SNP selection was developed so that a single tag SNP would be selected for each LD bin. Only those SNPs deemed candidate tag-SNPs by ldSelect with a minor allele frequency (MAF) of greater than or equal to 0.05 were considered for further selection. Tag-SNPs were ultimately selected based upon a functional ranking system wherein non-synonymous coding SNPs were preferentially selected among the tag-SNP candidates in each LD bin, followed by synonymous coding SNPs, SNPs from 5' untranslated regions (UTRs), SNPs from 3' UTRs, and finally SNPs from intronic regions. Seven SNPs were required to tag the SERPING1 haplotypes and were selected for genotyping.
###end p 22
###begin title 23
Genotyping
###end title 23
###begin p 24
The seven tag-SNPs were genotyped on genomic DNA extracted from peripheral blood leukocytes using TaqMan assays. Clustering of genotypes was inspected for separation between genotypes and accuracy of genotype calls. Quality control for genotype call was assessed by concordance for the control CEPH trio DNA replicates and two sample replicates within each 96 well plate. Randomly selected cases (25 subjects) and controls (25 subjects) were subjected to bi-directional DNA sequencing to determine the accuracy of genotyping with  in a masked fashion.
###end p 24
###begin title 25
Statistics
###end title 25
###begin p 26
###xml 611 620 611 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1.</italic>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 788 796 788 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 1104 1112 1104 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 1188 1191 1188 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1201 1210 1201 1210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 1211 1216 1211 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 1237 1243 1237 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB/C2</italic>
###xml 1245 1248 1245 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB</italic>
###xml 1255 1257 1255 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 1266 1268 1266 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 1335 1343 1335 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
Upon receipt of genotype intensities and processing as described above, all SNPs were noted to be in Hardy-Weinberg equilibrium. Single SNP analyses on genotype distributions were performed in SAS version 8 (SAS Institute, Cary, NC) using logistic regression assuming a log-additive genetic model where SNPs were coded as 0, 1, or 2 for the number of minor alleles and the corresponding p-values were calculated based on the score test statistics. Fisher's exact tests were also performed on genotype distributions. Haplotype analyses were completed using the score test that consisted of the seven SNPs across SERPING1. We also performed haplotype analysis with a 3-SNP-sliding-window approach, as implemented in haplo.stats [50] using R statistical software. Interaction effect between SERPING1 SNPs and smoking status (defined as ever, never) on AMD status was evaluated under a log-additive model with logistic regression using two main effect terms (genotype for each SNP and smoking status) and their interaction term, and assessed by a likelihood ratio test. We also evaluated interaction between SERPING1 SNPs and other major genetics risks for AMD including complement factor H (CFH, Y402H), LOC387715/HTRA1 (tagging SNP A69S), CFB/C2 (CFB, L9H; C2, ), and C3 (R102G and P314L). To investigate the effect of the seven SNPs of SERPING1 including  on AMD subtypes, likelihood ratio tests were performed considering controls as baseline. Haplotype analyses for AMD subtypes were also performed using a likelihood ratio test. Age is confounded with diagnosis (i.e., the cases are older than the controls), thus correction for age might reduce any detectable genetic effect and was not employed. Nominal p-values are reported.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 51 55 <span type="species:ncbi:162683">Mayo</span>
Association between individual SNPs and AMD in the Mayo subjects
###end title 28
###begin p 29
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
None of the seven SNPs tagging SERPING1 haplotypes (including ) were associated with AMD subjects compared to controls without AMD (Table 2). Because of the previously reported association between  and AMD, we sought to determine the accuracy of genotyping using DNA sequencing. The genotype for 50 subjects determined by DNA sequencing was in complete agreement with the TaqMan assay genotype calls. Thus, the absence of association could not be explained by inaccurate genotyping.
###end p 29
###begin title 30
###xml 56 64 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 103 107 <span type="species:ncbi:162683">Mayo</span>
Distribution of genotypes for the seven tag-SNPs across SERPING1 and their association with AMD in the Mayo subjects
###end title 30
###begin p 31
###xml 128 132 <span type="species:ncbi:162683">Mayo</span>
The seven single-nucleotide polymorphisms (SNPs) were tested for association with age-related macular degeneration (AMD) in the Mayo subjects and none was observed.
###end p 31
###begin title 32
Linkage disequilibrium
###end title 32
###begin p 33
###xml 99 107 99 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
###xml 286 294 286 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 381 389 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 171 175 <span type="species:ncbi:162683">Mayo</span>
###xml 342 346 <span type="species:ncbi:162683">Mayo</span>
###xml 487 491 <span type="species:ncbi:162683">Mayo</span>
To verify that our genotyping results were similar to other Caucasian populations genotyped across SERPING1, we compared the pattern of linkage disequilibrium (LD) in the Mayo subjects to the international  Caucasian subjects using  [48,51]. Moderate to high LD was observed across the SERPING1 locus and a similar pattern was present in the Mayo subjects and  Caucasian subjects (Figure 1). The similar pattern of LD further supports the accuracy of genotyping of all seven SNPs in the Mayo subjects.
###end p 33
###begin p 34
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 69 73 <span type="species:ncbi:162683">Mayo</span>
Linkage disequilibrium (LD) across the SERPING1 locus in  (left) and Mayo subjects (right). A similar LD pattern was observed for the two independent groups of Caucasian subjects. Numbers in the squares represent r2 estimates, while colors represent D' estimates (from none or white, to complete or red).
###end p 34
###begin title 35
Haplotype studies
###end title 35
###begin p 36
###xml 36 44 36 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 159 166 159 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 250 257 250 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 331 339 331 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 58 62 <span type="species:ncbi:162683">Mayo</span>
###xml 222 226 <span type="species:ncbi:162683">Mayo</span>
Comparison of haplotypes across the SERPING1 locus in the Mayo subjects and the international  Caucasian subjects showed a similar distribution of haplotypes (Table 3). Further, no haplotype was associated with AMD in the Mayo subjects (p=0.14-0.97, Table 3). A 3-SNP sliding window analysis did not reveal association between the SERPING1 haplotypes and AMD (p=0.13-0.67).
###end p 36
###begin title 37
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 36 40 <span type="species:ncbi:162683">Mayo</span>
SERPING1 haplotypes observed in the Mayo subjects and Caucasian subjects from the International  project
###end title 37
###begin p 38
###xml 136 143 136 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 167 175 167 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 261 265 <span type="species:ncbi:162683">Mayo</span>
Haplotypes with a frequency of 5% or higher are shown. The single-nucleotide polymorphism (SNP) order (left to right) is the same as in Table 1. Haplotypes across the SERPING1 locus were tested for association with age-related macular degeneration (AMD) in the Mayo subjects and none was observed.
###end p 38
###begin title 39
Replication study
###end title 39
###begin p 40
###xml 267 274 267 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 147 151 <span type="species:ncbi:162683">Mayo</span>
Given the demonstrated accuracy of genotyping, we sought to determine if the absence of association could be due to a type II error arising in the Mayo subject group. The most highly associated variant in the previous report () was genotyped on 1,541 AREDS subjects (Table 4) and no association with AMD was observed (p=0.45).
###end p 40
###begin title 41
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
Comparison of the association observed between AMD and the SERPING1 variant  in four subject groups
###end title 41
###begin p 42
###xml 150 154 <span type="species:ncbi:162683">Mayo</span>
Allele frequencies and genotype counts are shown for all four subject groups genotyped on  to date. The differences between cases and controls in the Mayo and AREDS subjects did not reach statistical significance.
###end p 42
###begin title 43
AMD subtype analysis
###end title 43
###begin p 44
###xml 307 311 <span type="species:ncbi:162683">Mayo</span>
To determine if the absence of association between AMD and  could be due to differences in the distribution of AMD subtypes in the different subject groups, we stratified the AMD subjects into early AMD, primary geographic atrophy, and exudation. Subgroup analysis using the seven tag-SNPs genotyped on the Mayo subjects revealed no evidence for association with any AMD subtype (early AMD, p=0.43-0.88; geographic atrophy, p=0.13-0.96; exudation, p=0.05-0.66). Similarly, no association between  genotypes and AMD subtypes were observed in the AREDS subjects (p=0.17-0.97). No haplotype was consistently associated with any AMD subtype (p=0.09-0.98).
###end p 44
###begin title 45
Interaction with other genetic risks for AMD
###end title 45
###begin p 46
###xml 271 279 271 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 448 451 448 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 461 472 461 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2/HTRA1</italic>
###xml 515 521 515 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB/C2</italic>
###xml 523 526 523 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFB</italic>
###xml 533 535 533 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
###xml 544 546 544 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C3</italic>
###xml 180 184 <span type="species:ncbi:162683">Mayo</span>
We further sought to determine if the absence of an effect of  on AMD risk might be explained by differences between modifiable risk factors and other genetic risks for AMD in the Mayo subjects. We observed no interaction between smoking categorized as ever or never and SERPING1 SNPs using logistic regression (p=0.25-0.52). We also found no interaction (p=0.68-0.98) between  and other major genetics risks for AMD including complement factor H (CFH, Y402H), ARMS2/HTRA1 (tagging SNP A69S), complement components CFB/C2 (CFB, L9H; C2, ), and C3 (R102G and P314L).
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 72 80 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 191 199 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
We were unable to replicate the previously reported association between SERPING1 and AMD using two independent groups of subjects [13]. Our study comprehensively assessed common variation in SERPING1 and specifically the SNP () most highly associated with AMD in the previous study [13].
###end p 48
###begin p 49
###xml 65 73 65 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
The previous study observed several SNPs (, , , , , and ) across SERPING1 that were associated with AMD [13]. We genotyped three of these SNP (, , and ) and observed no association with AMD. Although some investigators have felt that observing association from SNPs near the initial disease associated SNP provides additional support for the association, we have observed otherwise [11]. This situation arises secondary to linkage disequilibrium and supports accurate genotyping, but does not protect against a type I error [11].
###end p 49
###begin p 50
###xml 735 743 735 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 834 842 834 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
We recognize that a particular group of subjects may miss a valid association (type II error) or show false association (type I error). Several causes for such observations exist including invalid genotyping, population stratification, non-random sampling of the underlying population, and differences in non-randomized features of the cases and controls such as disease subtypes. For these reasons, we validated the genotyping with a second independent assay, studied two independent populations, and extensively studied the disease subgroups and similarities between our Caucasian populations and those genotyped elsewhere (). All of these analyses supported the validity of our study and failed to provide evidence for an effect of SERPING1 SNPs on AMD. Genotyping of additional groups of subjects will be required to determine if SERPING1 SNPs are associated with AMD in selected populations. Nonetheless, a major effect on AMD is unlikely.
###end p 50
###begin p 51
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 309 316 309 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
Genotyping errors can reduce power and are thus of particular concern in a study that fails to replicate a previous observation. The previous study used an Illumina BeadChip platform in one group of subjects and an assay on demand TaqMan method in a second independent group of subjects [13] for genotyping  (Table 4). Eight additional SNPs were genotyped using a third (KBioscience, Hoddesdon, UK) platform. Thus, genotyping errors seem unlikely to have caused a type I error in the previous report. We employed the same genotyping assay (TaqMan, Foster City, CA) used on one of their subject groups on both of our groups of subjects and performed DNA sequencing to confirm genotyping results. Genotyping problems seem unlikely to explain the differences between the studies.
###end p 51
###begin p 52
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 383 386 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 478 486 478 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERPING1</italic>
###xml 64 70 <span type="species:ncbi:9606">humans</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
SERPING1 is expressed in the neural retina, RPE, and choroid of humans [13] and is likely to play a role in regulating the complement system in the eye. Mutations in SERPING1 cause hereditary angioedema, but there is no known phenotypic overlap with AMD such as had been established with atypical hemolytic uremic syndrome or glomerulonephritis arising in patients with mutations in CFH [52]. In summary, we were unable to replicate the association between genetic variation in SERPING1 and AMD in two large and well characterized Caucasian subject groups and no compelling biologic evidence is available to support a role for the C1 inhibitor in AMD at this time.
###end p 52
###begin title 53
Acknowledgments
###end title 53
###begin p 54
###xml 234 238 <span type="species:ncbi:162683">Mayo</span>
The research was supported by EY014467, the Foundation Fighting Blindness, Owing Mills, MD, the American Health Assistance Foundation, Clarksburg, MD, unrestricted departmental grants from Research to Prevent Blindness, New York, NY, Mayo Foundation, Rochester, MN, and Seoul National University Bundang Hospital, Seoul, Korea.
###end p 54
###begin title 55
References
###end title 55
###begin article-title 56
Prevalence of age-related macular degeneration in the United States.
###end article-title 56
###begin article-title 57
Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body.
###end article-title 57
###begin article-title 58
Complement activation and inflammatory processes in Drusen formation and age related macular degeneration.
###end article-title 58
###begin article-title 59
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 59
###begin article-title 60
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 60
###begin article-title 61
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 61
###begin article-title 62
AMD Genetics Clinical Study Group, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
###end article-title 62
###begin article-title 63
Variation in complement factor 3 is associated with risk of age-related macular degeneration.
###end article-title 63
###begin article-title 64
Complement C3 variant and the risk of age-related macular degeneration.
###end article-title 64
###begin article-title 65
C3 R102G polymorphism increases risk of age-related macular degeneration.
###end article-title 65
###begin article-title 66
Evaluation of clustering and genotype distribution for replication in genome wide association studies: the age-related eye disease study.
###end article-title 66
###begin article-title 67
Molecular genetics of AMD and current animal models.
###end article-title 67
###begin article-title 68
Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study.
###end article-title 68
###begin article-title 69
Association of HLA class I and class II polymorphisms with age-related macular degeneration.
###end article-title 69
###begin article-title 70
Missense variations in the fibulin 5 gene and age-related macular degeneration.
###end article-title 70
###begin article-title 71
Elastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
###end article-title 71
###begin article-title 72
Variation near complement factor I is associated with risk of advanced AMD.
###end article-title 72
###begin article-title 73
Mitochondrial DNA haplogroups and age-related maculopathy.
###end article-title 73
###begin article-title 74
Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition.
###end article-title 74
###begin article-title 75
Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration.
###end article-title 75
###begin article-title 76
Apolipoprotein E gene and early age-related maculopathy: the Atherosclerosis Risk in Communities Study.
###end article-title 76
###begin article-title 77
Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration.
###end article-title 77
###begin article-title 78
Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD).
###end article-title 78
###begin article-title 79
Joint effects of smoking history and APOE genotypes in age-related macular degeneration.
###end article-title 79
###begin article-title 80
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy.
###end article-title 80
###begin article-title 81
Genetic association of apolipoprotein E with age-related macular degeneration.
###end article-title 81
###begin article-title 82
Toll-like receptor polymorphisms and age-related macular degeneration.
###end article-title 82
###begin article-title 83
Toll-like receptor 3 and geographic atrophy in age-related macular degeneration.
###end article-title 83
###begin article-title 84
Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration.
###end article-title 84
###begin article-title 85
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.
###end article-title 85
###begin article-title 86
Susceptibility genes for age-related maculopathy on chromosome 10q26.
###end article-title 86
###begin article-title 87
An immunologic study on age-related macular degeneration.
###end article-title 87
###begin article-title 88
Autoantibodies to retinal astrocytes associated with age-related macular degeneration.
###end article-title 88
###begin article-title 89
###xml 136 153 <span type="species:ncbi:9541">cynomolgus monkey</span>
###xml 155 174 <span type="species:ncbi:9541">Macaca fascicularis</span>
Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis).
###end article-title 89
###begin article-title 90
Circulating anti-retinal antibodies as immune markers in age-related macular degeneration.
###end article-title 90
###begin article-title 91
Oxidative damage-induced inflammation initiates age-related macular degeneration.
###end article-title 91
###begin article-title 92
The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration.
###end article-title 92
###begin article-title 93
Complement 1 inhibitor is a regulator of the alternative complement pathway.
###end article-title 93
###begin article-title 94
Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease.
###end article-title 94
###begin article-title 95
Biological activities of C1 inhibitor.
###end article-title 95
###begin article-title 96
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema.
###end article-title 96
###begin article-title 97
The effect of sequence variations within the coding region of the C1 inhibitor gene on disease expression and protein function in families with hereditary angio-oedema.
###end article-title 97
###begin article-title 98
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Detection of C1 inhibitor (SERPING1/C1NH) mutations in exon 8 in patients with hereditary angioedema: evidence for 10 novel mutations.
###end article-title 98
###begin article-title 99
Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q.
###end article-title 99
###begin article-title 100
Age-related macular degeneration-a genome scan in extended families.
###end article-title 100
###begin article-title 101
The Wisconsin age-related maculopathy grading system.
###end article-title 101
###begin article-title 102
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
###end article-title 102
###begin article-title 103
The International HapMap Consortium
###end article-title 103
###begin article-title 104
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.
###end article-title 104
###begin article-title 105
Score tests for association between traits and haplotypes when linkage phase is ambiguous.
###end article-title 105
###begin article-title 106
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 106
###begin article-title 107
Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis.
###end article-title 107

